Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition capable of inhibiting proliferation of tumor cells

A tumor cell proliferation and tumor cell technology, which can be used in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., can solve problems such as no reports of the combined use of EGCG and Doxorubicin, and achieve enhanced anti-tumor effects, reduced dosage and drug costs. , the effect of increasing the inhibition rate

Inactive Publication Date: 2012-07-04
FUDAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, there is no report on the combined use of EGCG and Doxorubicin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition capable of inhibiting proliferation of tumor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Synergistic effect of EGCG and Doxorubicin

[0031] In SK-hep-1 cells, the synergistic effect of EGCG and Doxorubicin is more significant. The concentration of immobilized Doxorubicin was 0.05 μM, and the concentration of EGCG was 1, 5, 10, 15, 20, among which the best effect was 0.05:20. The results are shown in the table below.

[0032] This example further verified the combined effect of EGCG and Doxorubicin, and the results proved that the CI values ​​were all less than 1 within a certain concentration range, and the two drugs had a synergistic effect. The results showed that the combined use of EGCG and Doxorubicin could improve the antitumor effect of Doxorubicin.

[0033] Table 1

[0034] Doxorubicin drug concentration (uM) EGCG drug concentration (uM) Doxorubicin monotherapy inhibition rate (%) Doxorubicin-EGCG combined inhibition rate (%) SK-hep-1 0.05 20 60.75 73.7

Embodiment 2

[0035] Example 2 EGCG has a synergistic effect with Doxorubicin

[0036] A fixed concentration of EGCG was administered in combination with Doxorubicin in five tumor cell lines. The following King's formula Q value was used to evaluate the combination effect.

[0037] Q=Ea+b / (Ea+Eb-Ea×Eb)

[0038] Among them, Ea+b is the inhibition rate of combined drugs, and Ea and Eb are the inhibition rates of drug A and drug B respectively;

[0039] The numerator represents the actual measured combined inhibition rate of the two drugs, and the denominator is the expected combined inhibition rate.

[0040] The range of Q=0.85-1.15 means simple addition, the range of Q=1.15-2 means enhancement, Q>2 means obvious enhancement, Q<0.55-0.85 means antagonistic effect, and Q<0.55 means obvious antagonism.

[0041] The results show that EGCG and Doxorubicin have a certain synergistic effect in specific cell lines, indicating that EGCG can enhance the anti-tumor activity of existing anti-live...

Embodiment 3

[0046] Example 3 Toxic and side effects of EGCG on the growth of xenograft tumors in nude mice

[0047] BALB / C-nu / nu nude mice were fed for 4-6 weeks under specific pathogen-free (SPF) conditions. Take 3×10 SK-Hep1 cells 6 The injection was in the right axilla of nude mice. After tumor formation, the control group was intraperitoneally injected with normal saline every day; the sodium carboxymethylcellulose group was orally given normal saline containing 0.5% sodium carboxymethylcellulose every day; the dose of sorafenib group was 60 mg / kg body weight / day, Oral administration; the dose of EGCG group was 25 mg / kg body weight / day or 50 mg / kg body weight / day, intraperitoneal injection. The SK-Hep1 cell nude mouse model was administered for 13 days.

[0048] 1. Effect of EGCG on body weight of nude mice

[0049] Changes in body weight in nude mice are an indicator of chemotherapeutic drug toxicity. Detecting the changes in the body weight of nude mice in the xenograft tum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the fields of medicines and gene engineering and provides a medicinal composition capable of inhibiting proliferation of tumor cells. The medicinal composition comprises gallocatechin epicatechol gallate and doxorubicine which serve as active ingredients and necessary pharmaceutical auxiliary materials, wherein the molar ratio of the gallocatechin epicatechol gallate to the doxorubicine is (400:1) to (20:1). Tests prove that the composition prepared from the gallocatechin epicatechol gallate and the doxorubicine, or prepared by combining the doxorubicine with the gallocatechin epicatechol gallate can obviously improve the curative effect of the doxorubicine of inhibiting proliferation of the tumor cells. The medicinal composition basically does not have toxicity to livers and kidneys of nude mice; and the gallocatechin epicatechol gallate in the active ingredients is rich in resources and low in price, so the tumor inhibition ratio is increased and the treatment cost of tumor patients is reduced.

Description

technical field [0001] The invention belongs to the fields of medicine and genetic engineering, and relates to a composition for inhibiting tumor cell proliferation, in particular to a composition for inhibiting tumor cell proliferation containing epigallocatechin gallate (EGCG) and doxorubicin. Background technique [0002] Adriamycin, namely Adriamycin (Doxorubicin, ADM), aliases: hydroxydaunorubicin, hydroxydaunomycin, doxorubicin, ADR. Doxorubicin is an anti-tumor antibiotic that can inhibit the synthesis of RNA and DNA. It has the strongest inhibitory effect on RNA and has a wide anti-tumor spectrum. Cyclic tumor cells have a killing effect. It is mainly applicable to acute leukemia, and is effective for acute lymphoblastic leukemia and myeloid leukemia. It is generally used as a second-line drug, that is, it can be considered when the first-line drug is resistant. Malignant lymphoma, can be used as the first drug alternately. This product is a broad-spectrum antineo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/353A61P35/00
Inventor 余龙张明君刘祖龙朱恒锐丁丽娅
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com